Skip to content

Extraocular, metastatic and trilateral disease

TL;DR — Orbital, nodal, marrow/bone and CNS retinoblastoma are distinct risk states that require systemic staging and multimodality therapy. COG ARET0321 achieved one-year event-free survival of 88.1% in stage II–III and 82.6% in stage IVa, but only 28.3% in stage IVb/trilateral disease, with treatment-related deaths. Trilateral retinoblastoma is an intracranial embryonal tumour in heritable predisposition, not metastasis from the eye. Baseline brain MRI is useful; repeated MRI schedules remain contested because detection yield and anaesthesia burden differ by pineal appearance.

Decision-relevant evidence

  • ARET0321 enrolled 57 eligible patients; one-year event-free survival was 88.1% (90% CI 66.6–96.2) for stage II–III, 82.6% (61.0–92.9) for stage IVa and 28.3% (12.7–46.2) for stage IVb/trilateral. Toxicity was substantial and included two therapy-related deaths (Dunkel 2022, PMID 35820112; NCT00554788). CNS involvement, not metastasis as such, is what the regimen fails to control.

  • Orbital (IRSS stage III) disease responds to multimodal therapy but the reported outcomes diverge sharply with setting. A randomized comparison in 54 children gave four-year survival of 63% (95% CI 0.41–0.79) with VEC versus 25% (0.08–0.46) with an alternating five-drug regimen, CNS relapse being the leading cause of death in both arms (Chawla 2016, PMID 27449712). A prospective 28-patient study of neoadjuvant chemotherapy, enucleation, radiotherapy and adjuvant chemotherapy reported overall survival 40.4% and event-free survival 33.33% at 26.3 months, with viable tumour still present in 21 of 22 enucleated specimens (95%) and bilateral disease predicting worse event-free (P = 0.0006) and overall survival (P = 0.0081) (Radhakrishnan 2012, PMID 22463820). No standard protocol is agreed for orbital disease (Ali 2011, PMID 21546735).

  • Extra-orbital metastatic disease remains largely fatal outside trials. In 81 patients treated over 21 years at a Mexican referral centre, the commonest metastatic site was the central nervous system (83.9%); 89.2% of the 74 treated with chemotherapy achieved a complete initial response, yet 56 died with progressive disease, all 15 who received no radiotherapy died with active tumour, and only four were alive and disease-free at 33–144.3 months (Leal-Leal 2006, PMID 16632438). A high initial response rate in this disease does not predict cure.

  • Extraocular presentation is a function of access rather than biology: cT4 disease occurred in 0.8% of high-income versus 42.9% of low-income children in the 2017 global cohort (PMID 35839812), and the earlier global cross-section by national income level documented the same gradient (Fabian 2020, PMID 32105305).

  • A meta-analysis of 197 trilateral cases found 79% of patients with pineoblastoma had their retinoblastoma diagnosed before 12 months of age, while baseline MRI at retinoblastoma diagnosis missed 89% of the later-diagnosed pineal tumours; modelling an additional scan at 29 months detected 53% of pineoblastomas while still asymptomatic, rising to 72%, 87% and 92% with two, three and four extra scans (de Jong 2022, PMID 33939299).

  • An earlier meta-analysis of 138 pineal trilateral cases put the screening burden in explicit numbers: 21 of 22 asymptomatic patients (95%) were diagnosed before 40 months (median 16, IQR 9–29); age at pineal diagnosis was independent of age at retinoblastoma diagnosis (P = 0.44) and of laterality and treatment; the lead time from asymptomatic to symptomatic disease was about one year; and six-monthly MRI to 36 months would require at least 311 scans to find one asymptomatic pineal tumour and 776 to save one life (de Jong 2020, PMID 32061409).

  • A 607-patient prospective cohort estimated trilateral risk at 3.78% in heritable disease and found that following all cystic pineal glands required 494 follow-up scans to detect one pineal tumour, against 22 when follow-up was restricted to suspicious glands. Screening sensitivity was 25% for pineal and 80% for non-pineal trilateral disease, with specificity 100%; four of five non-pineal trilateral tumours were caught on the baseline scan (de Bloeme 2024, PMID 38992673).

  • These three studies are not in conflict about the facts but about what to do with them: modelling supports adding timed scans, while prospective yield data argue against following unremarkable pineal cysts. The unresolved question is the interval and trigger, not whether baseline imaging is warranted.

  • Trilateral retinoblastoma has been recognised since the early 1980s as intracranial neuroblastic tumour arising in association with bilateral or familial retinoblastoma (Bader 1980, PMID 6106753; Zimmerman 1983, PMID 6864422; Meadows 1986, PMID 3784984), and ectopic non-pineal presentations continue to be reported (Mattavelli 2025, PMID 40043725).

  • Trilateral disease is not more frequent after neonatal diagnosis than after later diagnosis, despite the germline enrichment of neonatal cases (Kivelä 2017, PMID 28695165) — a point that matters because it separates "diagnosed early" from "at higher trilateral risk".

Clinical and research frame

Domain Operational meaning Evidence boundary
IRSS II–III Microscopic/regional/orbital Chemotherapy ± radiotherapy/local control
IRSS IVa Hematogenous non-CNS metastasis Intensive chemotherapy and stem-cell rescue
IRSS IVb CNS involvement Lowest EFS; unmet therapeutic need
Trilateral Pineal/suprasellar embryonal tumour Heritable predisposition; not ocular metastasis
Baseline MRI Brain/orbits Staging plus intracranial screen

Interpretation rules

  • Keep the child-level endpoints of survival and metastasis separate from the eye-level endpoint of globe salvage.

  • Report initial stage, laterality, heritability, prior treatment and follow-up; otherwise comparisons are not transportable.

  • A retrospective eye series estimates performance in selected eyes; it does not establish superiority over another route.

  • Absence of metastasis in a small series is a safety observation, not proof that risk is zero.

  • Treatment-era effects matter because external-beam radiotherapy, systemic chemotherapy, IAC and intravitreal therapy create different late-risk profiles.

  • Income stratum and access are effect modifiers, not background descriptors (Global Retinoblastoma Study Group 2022, PMID 35839812).

Evidence register

The following records were each retrieved live from PubMed E-utilities on 2026-09-01 and re-fetched live during the independent audit on the same date. Every identifier below resolved, and its author, year, journal and title matched the citation as written. Inclusion records the evidence base for this page; a register entry asserts that the record exists and is on topic, not that it supports a specific effect estimate.

PMID Year Study or review Role in this page
35820112 2022 Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). Topic-resolved source (Dunkel 2022, PMID 35820112)
33939299 2022 Asynchronous pineoblastoma is more likely after early diagnosis of retinoblastoma: a meta-analysis. Topic-resolved source (de 2022, PMID 33939299)
38992673 2024 Follow-up of Cystic Pineal Glands in Retinoblastoma Patients Does Not Increase Detection of Pineal Trilateral Retinoblastoma. Topic-resolved source (de 2024, PMID 38992673)
35839812 2022 The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. Topic-resolved source (Global 2022, PMID 35839812)
38804799 2024 Retinoblastoma - A comprehensive review, update and recent advances. Topic-resolved source (Nag 2024, PMID 38804799)
26023180 2016 Retinoblastoma. Topic-resolved source (Ortiz 2016, PMID 26023180)
28695165 2017 Neonatal Retinoblastoma. Topic-resolved source (Kivelä 2017, PMID 28695165)
16572402 2007 Trilateral retinoblastoma. Topic-resolved source (Antoneli 2007, PMID 16572402)
3784984 1986 Trilateral retinoblastoma. Topic-resolved source (Meadows 1986, PMID 3784984)
21849363 2011 MRI of retinoblastoma. Topic-resolved source (Razek 2011, PMID 21849363)
22106703 2011 Trilateral retinoblastoma. Topic-resolved source (Limn 2011, PMID 22106703)
40731848 2025 Update on Retinoblastoma Therapies. Topic-resolved source (Martínez 2025, PMID 40731848)
6864422 1983 "Trilateral retinoblastoma". Topic-resolved source (Zimmerman 1983, PMID 6864422)
6106753 1980 Trilateral retinoblastoma. Topic-resolved source (Bader 1980, PMID 6106753)
10881012 2000 Extraocular retinoblastoma. Topic-resolved source (Menon 2000, PMID 10881012)
10391556 1999 New insights into trilateral retinoblastoma. Topic-resolved source (Singh 1999, PMID 10391556)
16270206 2006 Trilateral retinoblastoma. Topic-resolved source (Larsen 2006, PMID 16270206)
29737052 2018 Retinoblastoma for Pediatric Ophthalmologists. Topic-resolved source (AlAli 2018, PMID 29737052)
40043725 2025 Presumed Ectopic Trilateral Retinoblastoma: Case Report. Topic-resolved source (Mattavelli 2025, PMID 40043725)
8218046 1993 Factors influencing metastasis in retinoblastoma. Topic-resolved source (Hungerford 1993, PMID 8218046)
3323180 1987 Intraocular and extraocular retinoblastoma. Topic-resolved source (Grabowski 1987, PMID 3323180)
21546735 2011 Orbital retinoblastoma: where do we go from here? Topic-resolved source (Ali 2011, PMID 21546735)
10921315 2000 [Retinoblastoma]. Topic-resolved source (Kaneko 2000, PMID 10921315)
32105305 2020 Global Retinoblastoma Presentation and Analysis by National Income Level. Topic-resolved source (Global 2020, PMID 32105305)
14522775 2003 Retinoblastoma associated with chromosomal 13q14 deletion mosaicism. Topic-resolved source (Kivelä 2003, PMID 14522775)
39735524 2024 Retinoblastoma in Ethiopian Children: Imaging Findings and Staging. Topic-resolved source (Woldeyohannes 2024, PMID 39735524)
21364467 2011 Bone marrow aspirations and lumbar punctures in retinoblastoma at diagnosis: correlation with IRSS staging. Topic-resolved source (Bakhshi 2011, PMID 21364467)
29337595 2017 Outcome of extraocular retinoblastoma in a resource limited center from low middle income country. Topic-resolved source (Pant 2017, PMID 29337595)
29043448 2017 [Retinoblastoma and retinocytoma (retinoma)]. Topic-resolved source (Metz 2017, PMID 29043448)
40334716 2025 Clinical Stage of Retinoblastoma Based on Presenting Signs of 4578 Patients from 121 Countries. Topic-resolved source (Yanagihara 2025, PMID 40334716)
22463820 2012 Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. Topic-resolved source (Radhakrishnan 2012, PMID 22463820)
23117972 2013 MRI findings at baseline and after neoadjuvant chemotherapy in orbital retinoblastoma (IRSS stage III). Topic-resolved source (Radhakrishnan 2013, PMID 23117972)
23787805 2013 Comparison of staging systems for extraocular retinoblastoma: analysis of 533 patients. Topic-resolved source (Chantada 2013, PMID 23787805)
31536438 2019 Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. Topic-resolved source (Luna-Fineman 2019, PMID 31536438)
34631159 2021 The Effects of Breastfeeding on Retinoblastoma Development: Results from an International Multicenter Retinoblastoma Survey. Topic-resolved source (Randhawa 2021, PMID 34631159)
22251556 2012 Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study. Topic-resolved source (Radhakrishnan 2012, PMID 22251556)
27172132 2015 Sirtuin1 Expression and Correlation with Histopathological Features in Retinoblastoma. Topic-resolved source (Batra 2015, PMID 27172132)
18937327 2009 Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Topic-resolved source (Chantada 2009, PMID 18937327)
25433413 2015 Assessment of early-stage optic nerve invasion in retinoblastoma using high-resolution 1.5 Tesla MRI with surface coils: a multicentre, prospective accuracy study with histopathological correlation. Topic-resolved source (Brisse 2015, PMID 25433413)
27977038 2017 Clinical Presentation and Outcomes of Stage III or Stage IV Retinoblastoma in 80 Asian Indian Patients. Topic-resolved source (Kaliki 2017, PMID 27977038)
27449712 2016 Multimodal Therapy for Stage III Retinoblastoma (International Retinoblastoma Staging System): A Prospective Comparative Study. Added by audit 2026-09-01 (Chawla 2016, PMID 27449712)
16632438 2006 Survival in extra-orbital metastatic retinoblastoma:treatment results. Added by audit 2026-09-01 (Leal-Leal 2006, PMID 16632438)
32061409 2020 Screening for Pineal Trilateral Retinoblastoma Revisited: A Meta-analysis. Added by audit 2026-09-01 (de Jong 2020, PMID 32061409)

Source chronology

Era marker PMID What the record contributes
1980 6106753 Trilateral retinoblastoma. (Bader 1980, PMID 6106753)
1983 6864422 "Trilateral retinoblastoma". (Zimmerman 1983, PMID 6864422)
1986 3784984 Trilateral retinoblastoma. (Meadows 1986, PMID 3784984)
1987 3323180 Intraocular and extraocular retinoblastoma. (Grabowski 1987, PMID 3323180)
1993 8218046 Factors influencing metastasis in retinoblastoma. (Hungerford 1993, PMID 8218046)
1999 10391556 New insights into trilateral retinoblastoma. (Singh 1999, PMID 10391556)
2000 10881012 Extraocular retinoblastoma. (Menon 2000, PMID 10881012)
2000 10921315 [Retinoblastoma]. (Kaneko 2000, PMID 10921315)
2003 14522775 Retinoblastoma associated with chromosomal 13q14 deletion mosaicism. (Kivelä 2003, PMID 14522775)
2006 16270206 Trilateral retinoblastoma. (Larsen 2006, PMID 16270206)
2007 16572402 Trilateral retinoblastoma. (Antoneli 2007, PMID 16572402)
2009 18937327 Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. (Chantada 2009, PMID 18937327)
2011 21364467 Bone marrow aspirations and lumbar punctures in retinoblastoma at diagnosis: correlation with IRSS staging. (Bakhshi 2011, PMID 21364467)
2011 21546735 Orbital retinoblastoma: where do we go from here? (Ali 2011, PMID 21546735)
2011 21849363 MRI of retinoblastoma. (Razek 2011, PMID 21849363)

Evidence limitations

  • Most intraocular treatment evidence is observational, single-centre and reported per eye; bilateral eyes within one child are statistically correlated.

  • Classification and treatment changed over time, producing stage migration and confounding by indication.

  • Rare metastatic and late-effect outcomes require multinational cohorts and decades of follow-up.

  • Verification is abstract-level. Every claim on this page was checked against the abstract of the record it cites during the independent audit on 2026-09-01; where an abstract could not support a claim, the claim was removed or restated as an explicit limit. Claims requiring full text beyond the abstract are not made here.

Open questions

  • How can CNS control improve without unacceptable treatment mortality? The current evidence register defines the design space but does not close the question.

  • Which heritable children benefit from serial MRI beyond baseline? The current evidence register defines the design space but does not close the question.

  • Can molecular residual-disease markers refine metastatic therapy? The current evidence register defines the design space but does not close the question.

References

  1. Dunkel IJ, et al. Intensive Multimodality Therapy for Extraocular Retinoblastoma: A Children's Oncology Group Trial (ARET0321). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022;40:3839-3847. PMID 35820112
  2. de Jong MC, et al. Asynchronous pineoblastoma is more likely after early diagnosis of retinoblastoma: a meta-analysis. Acta ophthalmologica. 2022;100:e47-e52. PMID 33939299
  3. de Bloeme CM, et al. Follow-up of Cystic Pineal Glands in Retinoblastoma Patients Does Not Increase Detection of Pineal Trilateral Retinoblastoma. American journal of ophthalmology. 2024;268:199-211. PMID 38992673
  4. Global Retinoblastoma Study Group. The Global Retinoblastoma Outcome Study: a prospective, cluster-based analysis of 4064 patients from 149 countries. The Lancet. Global health. 2022;10:e1128-e1140. PMID 35839812
  5. Nag A, et al. Retinoblastoma - A comprehensive review, update and recent advances. Indian journal of ophthalmology. 2024;72:778-788. PMID 38804799
  6. Ortiz MV, et al. Retinoblastoma. Journal of child neurology. 2016;31:227-36. PMID 26023180
  7. Kivelä TT, et al. Neonatal Retinoblastoma. Asia-Pacific journal of oncology nursing. 2017;4:197-204. PMID 28695165
  8. Antoneli CB, et al. Trilateral retinoblastoma. Pediatric blood & cancer. 2007;48:306-10. PMID 16572402
  9. Meadows A. Trilateral retinoblastoma. Medical and pediatric oncology. 1986;14:323-6. PMID 3784984
  10. Razek AA, et al. MRI of retinoblastoma. The British journal of radiology. 2011;84:775-84. PMID 21849363
  11. Limn YS, et al. Trilateral retinoblastoma. The Medical journal of Malaysia. 2011;66:156-7. PMID 22106703
  12. Martínez Arce CA, et al. Update on Retinoblastoma Therapies. Medicina (Kaunas, Lithuania). 2025;61. PMID 40731848
  13. Zimmerman LE. "Trilateral retinoblastoma". Journal of pediatric ophthalmology and strabismus. 1983;20:74. PMID 6864422
  14. Bader JL, et al. Trilateral retinoblastoma. Lancet (London, England). 1980;2:582-3. PMID 6106753
  15. Menon BS, et al. Extraocular retinoblastoma. Medical and pediatric oncology. 2000;35:75-6. PMID 10881012
  16. Singh AD, et al. New insights into trilateral retinoblastoma. Cancer. 1999;86:3-5. PMID 10391556
  17. Larsen S, et al. Trilateral retinoblastoma. Pediatric radiology. 2006;36:82. PMID 16270206
  18. AlAli A, et al. Retinoblastoma for Pediatric Ophthalmologists. Asia-Pacific journal of ophthalmology (Philadelphia, Pa.). 2018;7:160-168. PMID 29737052
  19. Mattavelli CCM, et al. Presumed Ectopic Trilateral Retinoblastoma: Case Report. Klinische Monatsblatter fur Augenheilkunde. 2025;242:426-428. PMID 40043725
  20. Hungerford J. Factors influencing metastasis in retinoblastoma. The British journal of ophthalmology. 1993;77:541. PMID 8218046
  21. Grabowski EF, et al. Intraocular and extraocular retinoblastoma. Hematology/oncology clinics of North America. 1987;1:721-35. PMID 3323180
  22. Ali MJ, et al. Orbital retinoblastoma: where do we go from here? Journal of cancer research and therapeutics. 2011;7:11-4. PMID 21546735
  23. Kaneko A. [Retinoblastoma]. Nihon rinsho. Japanese journal of clinical medicine. 2000;58:1413-8. PMID 10921315
  24. Global Retinoblastoma Study Group, et al. Global Retinoblastoma Presentation and Analysis by National Income Level. JAMA oncology. 2020;6:685-695. PMID 32105305
  25. Kivelä T, et al. Retinoblastoma associated with chromosomal 13q14 deletion mosaicism. Ophthalmology. 2003;110:1983-8. PMID 14522775
  26. Woldeyohannes AM, et al. Retinoblastoma in Ethiopian Children: Imaging Findings and Staging. Ethiopian journal of health sciences. 2024;34:39-46. PMID 39735524
  27. Bakhshi S, et al. Bone marrow aspirations and lumbar punctures in retinoblastoma at diagnosis: correlation with IRSS staging. Journal of pediatric hematology/oncology. 2011;33:e182-5. PMID 21364467
  28. Pant G, et al. Outcome of extraocular retinoblastoma in a resource limited center from low middle income country. Pediatric hematology and oncology. 2017;34:419-424. PMID 29337595
  29. Metz KA, et al. [Retinoblastoma and retinocytoma (retinoma)]. Der Pathologe. 2017;38:507-514. PMID 29043448
  30. Yanagihara RT, et al. Clinical Stage of Retinoblastoma Based on Presenting Signs of 4578 Patients from 121 Countries. Ophthalmology. 2025;132:1045-1053. PMID 40334716
  31. Radhakrishnan V, et al. Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology. 2012;119:1470-7. PMID 22463820
  32. Radhakrishnan V, et al. MRI findings at baseline and after neoadjuvant chemotherapy in orbital retinoblastoma (IRSS stage III). The British journal of ophthalmology. 2013;97:52-8. PMID 23117972
  33. Chantada GL, et al. Comparison of staging systems for extraocular retinoblastoma: analysis of 533 patients. JAMA ophthalmology. 2013;131:1127-34. PMID 23787805
  34. Luna-Fineman S, et al. Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019;37:2875-2882. PMID 31536438
  35. Randhawa JK, et al. The Effects of Breastfeeding on Retinoblastoma Development: Results from an International Multicenter Retinoblastoma Survey. Cancers. 2021;13:4773. PMID 34631159
  36. Radhakrishnan V, et al. Role of PET/CT in staging and evaluation of treatment response after 3 cycles of chemotherapy in locally advanced retinoblastoma: a prospective study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2012;53:191-8. PMID 22251556
  37. Batra A, et al. Sirtuin1 Expression and Correlation with Histopathological Features in Retinoblastoma. Ocular oncology and pathology. 2015;2:86-90. PMID 27172132
  38. Chantada GL, et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatric blood & cancer. 2009;52:218-22. PMID 18937327
  39. Brisse HJ, et al. Assessment of early-stage optic nerve invasion in retinoblastoma using high-resolution 1.5 Tesla MRI with surface coils: a multicentre, prospective accuracy study with histopathological correlation. European radiology. 2015;25:1443-52. PMID 25433413
  40. Kaliki S, et al. Clinical Presentation and Outcomes of Stage III or Stage IV Retinoblastoma in 80 Asian Indian Patients. Journal of pediatric ophthalmology and strabismus. 2017;54:177-184. PMID 27977038
  41. Chawla B, et al. Multimodal Therapy for Stage III Retinoblastoma (International Retinoblastoma Staging System): A Prospective Comparative Study. Ophthalmology. 2016;123:1933-9. PMID 27449712
  42. Leal-Leal CA, et al. Survival in extra-orbital metastatic retinoblastoma:treatment results. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2006;8:39-44. PMID 16632438
  43. de Jong MC, et al. Screening for Pineal Trilateral Retinoblastoma Revisited: A Meta-analysis. Ophthalmology. 2020;127:601-607. PMID 32061409